Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272856 · ClinicalTrials.gov registry record · Phase 1
Study on the Safety of Abatacept in Relapsing Polychondritis
A Phase 1 study of Relapsing Polychondritis, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT01272856 is a Phase 1 study of Relapsing Polychondritis that has completed, run by Benaroya Research Institute. The registered enrollment target is 4 participants, below the 1,373-participant average among 3 other Relapsing Polychondritis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01272856, a Phase 1 study of Relapsing Polychondritis, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of the study drug abatacept and see what effects (good and bad) it has in patients with relapsing polychondritis.
Conditions Studied
Interventions
- DRUG Abatacept
Study Locations (1)
Washington
- Virginia Mason Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01272856
The ClinicalTrials.gov registry entry for NCT01272856 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,373-participant average among 3 other Relapsing Polychondritis trials with a reported enrollment target (100% lower). The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Polychondritis appearing as the primary indexed condition, and to 1 intervention - of which Abatacept is the first listed.
NCT01272856 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01272856 about?
NCT01272856 is a clinical study titled "Study on the Safety of Abatacept in Relapsing Polychondritis". The purpose of this study is to test the safety of the study drug abatacept and see what effects (good and bad) it has in patients with relapsing polychondritis.
What is the current status of trial NCT01272856?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-01. Estimated completion is 2012-05.
What conditions does trial NCT01272856 study?
This clinical trial studies the following conditions: Relapsing Polychondritis.
What interventions are being tested in trial NCT01272856?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT01272856?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01272856 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Polychondritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.